Product category:
Spectroscopy
News Release from: Teraview | Subject: Terahertz imaging
Edited by the Laboratorytalk Editorial
Team on 10 October 2007
Terahertz imaging to replace dissolution
testing?
FDA study focussed upon a delayed release dosage form which employs coatings that are engineered to breakdown and release the drug in the lower intestinal tract
TeraView says its Terahertz imaging and spectroscopy products can be used in conjunction with wet dissolution testing to accelerate product development of tablets and capsules, and maintain in-spec performance during pharmaceutical manufacture This comes in the wake of a recent paper by the Food and Drug Administration (FDA) in the USA, which states that the speed and ease of Terahertz imaging may make it an attractive potential replacement for wet dissolution testing both in product development and eventually for process analysis
This article was originally published on Laboratorytalk on 2 Mar 2005 at 8.00am (UK)
Related stories
Reflective sampling in terahertz spectroscopy
The world's first terahertz spectrometer capable of making measurements in multiple sampling geometries combines reflective and transmission spectroscopy technology
First commercial terahertz imager in Japan
TeraView and Bruker Optics have deployed the first commercial terahertz imager in Japan to aid in the development of new pharmaceutical tablets and other solid forms, as well as root cause analysis
The product is a treatment for ulcerative colitis and Crohn's disease, and undesirable release of drug in the stomach and upper small intestine will lead to premature absorption and possible systemic side effects for the consumer.
The FDA found the tablets to dissolve erratically during conventional wet dissolution measurements so Terahertz imaging was used to accurately map the coating thickness.
The mean dissolution times were found to correlate with the average tablet coating thickness, suggesting that the coating thickness played a significant role to product design and performance.
Further reading
3D imaging makes waves in drug product R+D
Complete three-dimensional imaging of intact tablet cores and coatings is now possible thanks to the launch by TeraView of the first commercial terahertz (THz) imaging system, the TPI imaga 2000
Using in-line raw conductivity in USP 645
Monograph 645 of the United States Pharmacopeia has a direct impact worldwide on water analysis and quality in the pharmaceutical manufacturing industries
The study has recently been published in the Journal of Pharmaceutical Sciences.
Professor Michael Pepper, chief scientific officer of TeraView said: "This study demonstrates that Terahertz technology has a potential role to play alongside dissolution in the optimisation of therapeutic effectiveness of dosage forms during product development and stability assessment, as well as routine assessment of production quality to ensure uniformity between production lots".
According to Don Arnone, chief executive officer of TeraView: "Additional studies are required to demonstrate and understand to what extent Terahertz can be used alongside dissolution in other contexts.
"However, the evidence here suggests that our Terahertz products have the capacity to reduce drug development times and help ensure in-spec performance of product, thereby minimising the risk of regulatory non compliance for the industry and more rapidly providing consumers with improved pharmaceutical products".
TeraView's tablet imaging technology uses the Terahertz spectrum between light and radio waves and offers the advantage of being non-invasive and non-destructive.
Past studies have demonstrated how Terahertz uniquely provides structural images and chemical information on the contents of tablets and capsules which are invisible with conventional techniques.
• Teraview: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
